Central Retinal Vein Occlusion clinical trials at UC Davis
1 research study open to eligible people
A Study of Experimental Stem Cell Injection for Central Retinal Vein Occlusion (vision loss due to decreased blood supply in eye)
open to eligible people ages 18 years and up
This study evaluates whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from central retinal vein occlusion (CRVO). Half of the participants will receive immediate cellular therapy followed by sham therapy 6 months later, while the other half will receive immediate sham therapy followed by cellular therapy 6 months later. Participants will be followed for a total of 2 years.